FY2025 · ended Dec 31, 2025 · Revenue $761.41M, +12.8% YoY · Filed Feb 24, 2026
Corcept Therapeutics Inc (CORT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $761.4 million and net income of $99.7 million. Free cash flow was $141.8 million. As of Sep 30, 2026 it held $662.3 million in cash and investments and $9.0 million in total debt.
Revenue (TTM)
$963.65M
+30.0% vs year-ago TTM
Net income (TTM)
$162.29M
+52.9% vs year-ago TTM
Operating cash flow (TTM)
$198.11M
+21.1% vs year-ago TTM
Free cash flow (TTM)
$194.62M
+19.2% vs year-ago TTM
EPS (TTM)
$1.33
+52.5% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
106.37M
+0.8% vs prior year
Net cash
$653.32M
as of Sep 30, 2026
Operating margin
11.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CORT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1088856
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M |
| Diluted EPS | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| Operating cash flow | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M |
| Free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M |
| Stockholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M |
| Cash and investments | $532.4M | $603.2M | $425.4M | $436.6M | $335.8M |
| Total debt | $6.1M | $6.9M | $151,000 | $1.1M | $526,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 23, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Other events
|
Jun 17, 2026 | Jun 17, 2026 |
All 1001 Corcept Therapeutics Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.